Dengue Antibody Discovery


The MacAry Laboratory in CREATE-NUS-HUJ has detailed the development and thorough characterization of the first fully human monoclonal antibody from a patient at NUH recovered from Dengue infection. This antibody represents an excellent therapeutic candidate for treating dengue patients on the basis that it reduces dengue viral titres in infected blood by 50 thousand-fold within 2 hours of administration and does this at picomolar concentrations (the pharma standard for a good therapeutic candidate is one that gives a 10 fold reduction in virus at micromolar concentrations). This antibody represents the ‘essence’ of dengue immunity and thus our identification of its target on the virus (we’ve finely mapped the binding site) plus its mode of action (it blocks the virus from binding to its host cells) has important implications for the design and evaluation of new dengue vaccines. The antibody will also be employed as a new candidate therapy for Dengue in clinical trials scheduled for 2014.

For more information, watch the Reuters interview or read the article about the topic at the NUS Newshub.

Partners